Oreola Donini - Soligenix Insider

Soligenix Inc -- USA Stock  

USD 2.05  0.021  1.01%

Chief Scientific Officer and Sr. VP

Dr. Oreola Donini, Ph.D., is Senior Vice President, Chief Scientific Officer of Soligenix, Inc. Dr. Donini served as our Vice President of Preclinical Research and Development from August 15, 2013 until December 4, 2014. She has more than 15 years experience in drug discovery and preclinical development with startup biotechnology companies. From 2012 to 2013, Dr. Donini worked with ESSA Pharma Inc. as Vice President Research and Development. From 2004 to 2012, Dr. Donini worked with Inimex Pharmaceuticals Inc.,, lastly as Senior Director of Preclinical RD from 20072013. Prior to joining Inimex, she worked with Kinetek Pharmaceuticals Inc., developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a coinventor and leader of the Companys SGX94 innate defense regulator technology, developed by Inimex and subsequently acquired by the Company. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation andor chemotherapy treatment. These preclinical studies resulted in a successful Phase 1 clinical study and clearance of Phase 2 protocols for oral mucositis in head and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel Nterminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitors for the treatment of cancer
Age: 42  SVP Since 2014  Ph.D    
609-538-8200  http://www.soligenix.com
Donini received her PhD from Queen?s University in Kinston, Ontario, Canada and completed her postdoctoral work at the University of California.

Management Efficiency

The company has return on total asset (ROA) of (70.23) % which means that it has lost $70.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (330.88) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 1 records

SVP Since

Reed ClarkDimension Therapeutics Inc
2015

Entity Summary

Soligenix, Inc., a latestage biopharmaceutical company focused on developing and commercializing solutions to treat rare diseases primarily in the United States. Soligenix Inc (SNGX) is traded on Nasdaq Capital Markets in USA. It is located in NEW JERSEY, U.S.A and employs 16 people. Soligenix Inc was previously known as Soligenix Inc and was traded on Nasdaq Capital Markets under the symbol SNGX. Soligenix is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Soligenix Inc to your portfolio

Top Management

Soligenix Inc Leadership Team
Jerome Zeldis, Director
Richard Straube, President
Marco Brughera, Director
Oreola Donini, SVP, Ph.D
Gregg Lapointe, Director
Keith Brownlie, Director, CPA
Christopher Schaber, Chairman
Karen Krumeich, President
Joseph Warusz, President, CPA
Robert Rubin, Director
Anthony Lapointe, Director

Stock Performance

Soligenix Performance Indicators